This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Histologically or cytologically confirmed recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [High-grade serous carcinoma (HGSC), Grade 2/3 endometrioid carcinoma]
Patients whose BRCA 1/2 gene mutation status and/or Homologous Recombination Deficiency (HRD) status.
Patients who received platinum-based chemotherapy followed by PARP inhibitor maintenance therapy,
Patients who had received chemotherapy before participating in the clinical trial and responded to platinum-based chemotherapy.
Patients with a history of severe drug hypersensitivity or hypersensitivity to the investigational drug, its components, or drugs within the same class.
Individuals with dysphagia
Patients with a confirmed specific medical history or a past surgical history.
Patients with specific comorbidities or medical abnormalities.